跳至主要内容
临床试验/NCT03216889
NCT03216889已完成不适用

Cognitive Behavioral Therapy for Insomnia to Address Insomnia Symptoms in People With Multiple Sclerosis

University of Kansas Medical Center2 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2017年6月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
43
试验地点
2
主要终点
Insomnia Severity Index (ISI)

研究概览

简要总结

The purpose of this study is to learn if cognitive behavioral therapy for insomnia (CBT-I) will improve sleep quality, fatigue, and quality of life in individuals with multiple sclerosis (MS) with symptoms of insomnia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of MS by physician
  • Report of difficulty falling asleep, maintaining sleep, or waking up too early at least 3 nights/week for the past 6 months,
  • ≥10 on Insomnia Severity Index
  • English speaking
  • Core at least 24 on the Mini-Mental State Exam (MMSE) to indicate reduced risk of dementia

排除标准

  • Known untreated sleep disorder (such as sleep apnea or restless leg syndrome)
  • >4 on STOP BANG indicating high risk of sleep apnea
  • Increased risk of restless leg syndrome on Restless Legs Syndrome (RLS) Diagnosis Index
  • Nervous system disorder other than MS
  • Relapse and/or corticosteroid use in past 8 weeks

结局指标

主要结局

Insomnia Severity Index (ISI)

时间窗: Change from Baseline to Week 7

The ISI consists of 7 questions, each rated on a 0-4 scale. The range of scores on the ISI is 0-28, with a score of ≥ 10 suggesting clinical insomnia. The lower the score the less severe insomnia.

次要结局

  • Fatigue Severity Scale (FSS)(Change from Baseline to Week 7)
  • Pittsburgh Sleep Quality Index (PSQI)(Change from Baseline to Week 7)
  • Modified Fatigue Impact Scale (MFIS)(Change from Baseline to Week 7)
  • Multiple Sclerosis Impact Scale (MSIS)(Change from Baseline to Week 7)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Cognitive Behavioral Therapy for Insomnia to Address... | 临床试验